EGFR and non-small cell lung carcinoma: As shown in Figure 5A, pooled HR was 1.40 for OS (95% CI 1.21-1.61, p=0.0) based on 21 studies [10, 11, 15, 16, 18–20, 22–24, 26–28, 31, 32, 34, 39, 42, 47, 50, 51] comparing KRAS mutant NSCLC with KRAS and EGFR wild-type NSCLC, indicating a significant worse survival for KRAS mutant patients.